Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

MERCK KGAA

(MRK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Merck KGaA : The calm spell can be taken advantage of to put on new positions

05/24/2023 | 02:21am EDT
long trade
Live
Entry price : 165.75€ | Target : 180€ | Stop-loss : 159€ | Potential : 8.6%
Merck KGaA shares are locked into a trading range. This phase will eventually have to end with a return of a clear trend.
Investors have an opportunity to buy the stock and target the € 180.
Merck KGaA : Merck KGaA : The calm spell can be taken advantage of to put on new positions
Summary
  • According to Refinitiv, the company's ESG score for its industry is good.
  • Merck KGaA accounts for 4.85 % of our European Portfolio. A trade is currently open since 12/13/2022 with a purchase price of € 182.16. Discover the other 19 stocks of the European portfolio managed by the MarketScreener portfolio management team.

Strengths
  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • The company returns high margins, thereby supporting business profitability.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The opinion of analysts covering the stock has improved over the past four months.
  • Consensus analysts have strongly revised their opinion of the company over the past 12 months.
  • There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.

  • Weaknesses
    • With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
    • With an enterprise value anticipated at 3.57 times the sales for the current fiscal year, the company turns out to be overvalued.
    • The company is not the most generous with respect to shareholders' compensation.
    • For the last few months, analysts have been revising downwards their earnings forecast.
    Ratings chart
    Subsector Specialty & Advanced Pharmaceuticals
    1st jan.Capitalization (M$)Investor Rating
    MERCK KGAA-6.55%78 685
    KYOWA KIRIN CO. LTD.-10.10%10 434
    SK BIOPHARMACEUTICALS CO., ..1.53%4 472
    DOTTIKON ES HOLDING AG1.99%3 885
    CHANGCHUN BCHT BIOTECHNOLOG..-11.19%3 635
    ZHEJIANG JIUZHOU PHARMACEUT..-36.25%3 459
    YUHAN CORPORATION6.82%3 313
    BETTA PHARMACEUTICALS CO., ..-0.45%2 967
    INDIVIOR PLC-7.34%2 947
    SUPERNUS PHARMACEUTICALS, I..-0.62%1 931
    ZHEJIANG AUSUN PHARMACEUTIC..-10.38%1 290
    More Results

    ę MarketScreener.com 2023

    Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
    The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

    Financials
    Sales 2023 22 246 M 23 969 M 23 969 M
    Net income 2023 3 331 M 3 589 M 3 589 M
    Net Debt 2023 7 378 M 7 949 M 7 949 M
    P/E ratio 2023 22,0x
    Yield 2023 1,32%
    Capitalization 73 564 M 79 263 M 79 263 M
    EV / Sales 2023 3,64x
    EV / Sales 2024 3,31x
    Nbr of Employees 64 011
    Free-Float 29,7%
    Upcoming event on MERCK KGAA
    Income Statement Evolution
    Consensus
    Sell
    Buy
    Mean consensus BUY
    Number of Analysts 16
    Last Close Price 169,20 €
    Average target price 204,24 €
    Spread / Average Target 20,7%
    EPS Revisions
    Managers and Directors
    BelÚn Garijo Lˇpez Chairman-Executive Board & CEO
    Marcus Kuhnert Chief Financial Officer
    Wolfgang Heinz BŘchele Chairman-Supervisory Board
    Laura Matz Chief Science & Technology Officer
    Danny Bar-Zohar Head-Development & Executive Vice President
    MarketScreener: Created by Investors for Investors!
    100% Free Registration
    fermer